Clinical Trial Update: Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) [Phase 3]

View source ↗

Summary

A Phase 3 trial (NCT07190443) is evaluating adjuvant abemaciclib for locoregional recurrence in HR-positive, HER2-negative breast cancer; recruitment is ongoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Japanese Foundation for Cancer Research | Conditions: Breast Cancer, Locoregional Recurrence | Phase 3 | Status: RECRUITING